Market Place
Sourcing Support
All News #Library
Biotech
Corvus Pharma Investor Meeting To Showcase Soquelitinib Data
21 Apr 2026 //
GLOBENEWSWIRE
Corvus To Present At Oppenheimer Healthcare Life Sciences Conf
23 Feb 2026 //
GLOBENEWSWIRE
Corvus Pharma Confirms Positive Phase 1 Trial Data
20 Jan 2026 //
GLOBENEWSWIRE
Corvus Pharma To Report Cohort 4 Results Of Soquelitinib Trial
16 Jan 2026 //
GLOBENEWSWIRE
Corvus Pharma Unveils P1/1b Soquelitinib Data in T-Cell Lymphoma
08 Dec 2025 //
GLOBENEWSWIRE
Corvus Pharma Updates Business & Reveals Q3 Financials updates
04 Nov 2025 //
GLOBENEWSWIRE
Corvus Pharma To Unveil Soquelitinib Phase 1/1B T Cell Lymphoma
03 Nov 2025 //
GLOBENEWSWIRE
Corvus Pharma To Present At Guggenheim Healthcare Innovation Conf
31 Oct 2025 //
GLOBENEWSWIRE
Corvus Reports Interim Ph1b/2 Data in Renal Cell Cancer
17 Oct 2025 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Reports Q2 2025 Financial Results
07 Aug 2025 //
GLOBENEWSWIRE
Corvus Partner Angel Pharma get IND Approval for a Ph 1b/2 Trial
25 Jun 2025 //
GLOBENEWSWIRE
Corvus Pharma Initiates Phase 3 Trial Of Soquelitinib For PTCL
10 Sep 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Confirms Planned Initiation of CPI-818 Phase 3 Trial
06 Sep 2023 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Presents New CPI-818 Interim Data
15 Jun 2023 //
GLOBENEWSWIRE
Corvus Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition
17 Apr 2023 //
GLOBENEWSWIRE
CPI-818 Data Highlights Potential for ITK Inhibition as Immunotherapy Approach
03 Apr 2023 //
GLOBENEWSWIRE
Corvus to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition
14 Mar 2023 //
GLOBENEWSWIRE
Corvus Pharma Announces New Data Demonstrating CPI-818 Potential
21 Feb 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.